JP2022513363A5 - - Google Patents

Info

Publication number
JP2022513363A5
JP2022513363A5 JP2021546056A JP2021546056A JP2022513363A5 JP 2022513363 A5 JP2022513363 A5 JP 2022513363A5 JP 2021546056 A JP2021546056 A JP 2021546056A JP 2021546056 A JP2021546056 A JP 2021546056A JP 2022513363 A5 JP2022513363 A5 JP 2022513363A5
Authority
JP
Japan
Prior art keywords
glp1
fusion protein
pharmaceutical composition
gdf15 fusion
gdf15
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021546056A
Other languages
English (en)
Japanese (ja)
Other versions
JP7539902B2 (ja
JP2022513363A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/059029 external-priority patent/WO2020084496A1/en
Publication of JP2022513363A publication Critical patent/JP2022513363A/ja
Publication of JP2022513363A5 publication Critical patent/JP2022513363A5/ja
Priority to JP2024135217A priority Critical patent/JP2024170428A/ja
Application granted granted Critical
Publication of JP7539902B2 publication Critical patent/JP7539902B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021546056A 2018-10-22 2019-10-22 グルカゴン様ペプチド1(glp1)-増殖分化因子15(gdf15)融合タンパク質及びその使用 Active JP7539902B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024135217A JP2024170428A (ja) 2018-10-22 2024-08-14 グルカゴン様ペプチド1(glp1)-増殖分化因子15(gdf15)融合タンパク質及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862748603P 2018-10-22 2018-10-22
US62/748,603 2018-10-22
PCT/IB2019/059029 WO2020084496A1 (en) 2018-10-22 2019-10-22 Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024135217A Division JP2024170428A (ja) 2018-10-22 2024-08-14 グルカゴン様ペプチド1(glp1)-増殖分化因子15(gdf15)融合タンパク質及びその使用

Publications (3)

Publication Number Publication Date
JP2022513363A JP2022513363A (ja) 2022-02-07
JP2022513363A5 true JP2022513363A5 (cg-RX-API-DMAC10.html) 2022-10-27
JP7539902B2 JP7539902B2 (ja) 2024-08-26

Family

ID=70330680

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021546056A Active JP7539902B2 (ja) 2018-10-22 2019-10-22 グルカゴン様ペプチド1(glp1)-増殖分化因子15(gdf15)融合タンパク質及びその使用
JP2024135217A Pending JP2024170428A (ja) 2018-10-22 2024-08-14 グルカゴン様ペプチド1(glp1)-増殖分化因子15(gdf15)融合タンパク質及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024135217A Pending JP2024170428A (ja) 2018-10-22 2024-08-14 グルカゴン様ペプチド1(glp1)-増殖分化因子15(gdf15)融合タンパク質及びその使用

Country Status (24)

Country Link
US (3) US11713345B2 (cg-RX-API-DMAC10.html)
EP (2) EP4520343A3 (cg-RX-API-DMAC10.html)
JP (2) JP7539902B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210081389A (cg-RX-API-DMAC10.html)
CN (2) CN119751697A (cg-RX-API-DMAC10.html)
AU (2) AU2019368816B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021007376A2 (cg-RX-API-DMAC10.html)
CA (1) CA3116983A1 (cg-RX-API-DMAC10.html)
CL (1) CL2021000987A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021005051A2 (cg-RX-API-DMAC10.html)
CR (1) CR20210193A (cg-RX-API-DMAC10.html)
DO (1) DOP2021000075A (cg-RX-API-DMAC10.html)
EA (1) EA202191105A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP21028914A (cg-RX-API-DMAC10.html)
ES (1) ES3011982T3 (cg-RX-API-DMAC10.html)
IL (1) IL282297B2 (cg-RX-API-DMAC10.html)
JO (1) JOP20210084A1 (cg-RX-API-DMAC10.html)
MX (1) MX428581B (cg-RX-API-DMAC10.html)
MY (1) MY205905A (cg-RX-API-DMAC10.html)
PE (1) PE20211078A1 (cg-RX-API-DMAC10.html)
PH (1) PH12021550885A1 (cg-RX-API-DMAC10.html)
SA (1) SA521421825B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202103990QA (cg-RX-API-DMAC10.html)
WO (1) WO2020084496A1 (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
MY205905A (en) 2018-10-22 2024-11-20 Janssen Pharmaceutica Nv Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
CN113474363A (zh) * 2018-11-20 2021-10-01 詹森药业有限公司 用于降低体重和/或减少食物摄取量的gdf15类似物和方法
JP7536030B2 (ja) * 2019-03-08 2024-08-19 アムジエン・インコーポレーテツド 増殖分化因子15併用療法
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
US11981718B2 (en) * 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
WO2022221291A2 (en) * 2021-04-12 2022-10-20 University Of Florida Research Foundation Incorporated Compositions and methods for treating obesity
EP4351627A4 (en) * 2021-05-21 2025-06-04 Yuhan Corporation COMPOSITION FOR COMBINATION THERAPY COMPRISING A GROWTH DIFFERENTIATION FACTOR 15 VARIANT AND A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST
AU2022278933A1 (en) * 2021-05-21 2023-12-07 Yuhan Corporation Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
EP4619423A1 (en) * 2022-11-18 2025-09-24 Yuhan Corporation Dual function proteins and uses thereof
CN116813742A (zh) * 2022-11-22 2023-09-29 杭州博茵生物技术有限公司 人gdf-15抗原表位肽、抗原、抗体、试剂盒及应用
WO2024144431A1 (ru) * 2022-12-29 2024-07-04 Авва Фармасьютикалс Лтд Новый штамм-продуцент escherichia coli, продуцирующий гибридный белок cbd-hs-es-glp1, и способ получения полипептида glp-1
JP2026505740A (ja) * 2023-01-20 2026-02-18 コリア アドバンスト インスティチュート オブ サイエンス アンド テクノロジー Gfralを標的にするアンチセンスオリゴマー及びこの用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
SI1724284T1 (sl) * 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
ES2371072T3 (es) 2003-06-12 2011-12-27 Eli Lilly And Company Proteínas de fusión análogas de glp-1.
US20090099031A1 (en) 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
KR20090039787A (ko) 2006-07-18 2009-04-22 센토코 인코포레이티드 인간 glp-1 모방체, 조성물, 방법 및 용도
AR071874A1 (es) 2008-05-22 2010-07-21 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
CA2740632A1 (en) 2008-10-31 2010-05-06 St. Vincent's Hospital Sydney Limited Methods of prognosis in chronic kidney disease
MX2011007889A (es) 2009-02-06 2011-08-15 Syngenta Participations Ag Modificacion de enzima multidominio para la expresion en plantas.
TW201101990A (en) 2009-07-08 2011-01-16 zhen-zheng Huang Plant media
EP2456454A4 (en) 2009-07-20 2013-03-20 Univ Nat Cheng Kung FOR AV-3-INTEGRIN SELECTIVE POLYPEPTIDE AND PHARMACEUTICAL USES THEREOF ASSOCIATED WITH A HUMAN SERUM ALUMINUM (HSA) VARIATION
WO2012091564A2 (en) 2010-12-27 2012-07-05 Apo-T B.V. A cross-linking polypeptide that induces apoptosis
US8883735B2 (en) 2011-11-04 2014-11-11 Novartis Ag Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs
KR20140125803A (ko) 2012-01-26 2014-10-29 암젠 인크 성장 분화 인자 15(gdf-15) 폴리펩타이드들
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド 代謝障害を治療するための組成物および方法
KR102373193B1 (ko) * 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
ES3066738T3 (en) 2012-12-21 2026-05-14 Aveo Pharmaceuticals Inc Anti-gdf15 antibodies
NZ709913A (en) 2013-01-25 2019-05-31 Janssen Biotech Inc Kv1.3 antagonists and methods of use
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
CA2899170C (en) 2013-01-30 2022-08-02 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
AU2014283221A1 (en) * 2013-06-20 2015-12-03 Novo Nordisk A/S GLP-1 derivatives and uses thereof
LT3027642T (lt) * 2013-07-31 2020-10-12 Amgen Inc. Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai
GB201403794D0 (en) * 2014-03-04 2014-04-16 Univ Manchester Novel antimicrobial peptides
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
WO2015197446A1 (en) 2014-06-24 2015-12-30 Novo Nordisk A/S Mic-1 fusion proteins and uses thereof
JP6704358B2 (ja) 2014-07-30 2020-06-03 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害を治療するための組成物および使用方法
AU2015339134B2 (en) 2014-10-30 2021-06-17 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
CN106687128B (zh) 2014-10-31 2022-05-10 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
GB201512733D0 (en) 2015-07-20 2015-08-26 Genagon Therapeutics Ab Therapeutic agents for treating conditions associated with elevated GDF15
US20190000923A1 (en) 2015-12-22 2019-01-03 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
JP2019510739A (ja) 2016-02-29 2019-04-18 イーライ リリー アンド カンパニー Gfral受容体療法
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
KR102433503B1 (ko) 2016-05-24 2022-08-18 노보 노르디스크 에이/에스 Mic-1 화합물 및 이것의 사용
WO2018071493A1 (en) 2016-10-12 2018-04-19 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Mic-1化合物及其用途
MY205905A (en) 2018-10-22 2024-11-20 Janssen Pharmaceutica Nv Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
CN113474363A (zh) 2018-11-20 2021-10-01 詹森药业有限公司 用于降低体重和/或减少食物摄取量的gdf15类似物和方法

Similar Documents

Publication Publication Date Title
US11858975B2 (en) Multi-domain active protein for treating metabolic diseases
US8889619B2 (en) Fusion protein of Exendin-4 and its analog, preparation method and use thereof
JP7268202B2 (ja) 代謝性疾患を治療するための融合タンパク質
US8304386B2 (en) Long-acting growth hormone and methods of producing same
US10538586B2 (en) Compositions and methods for treating fatty tissue buildup
JP7282899B2 (ja) 線維芽細胞成長因子21変異体、その融合タンパク質とその使用
CN114621339B (zh) 一种长效glp-1衍生物
AU2020233876B2 (en) Growth differentiation factor 15 combination therapy
CN104010650A (zh) 长效生长激素及其生产方法
JP7058670B2 (ja) 増殖分化因子15融合タンパク質
WO2011020319A1 (zh) 调节血糖血脂的融合蛋白及其制备方法和应用
TW201414750A (zh) 用於治療代謝症狀的融合蛋白
JP2010031018A5 (cg-RX-API-DMAC10.html)
US12551541B2 (en) Albumin bound macromolecule tri-agonist activating GLP 1/GIP/glucagon receptors and methods therefor
US10736970B2 (en) Polypeptide complex of titin-telethonin beta-pleated sheet structure as polypeptide drug carrier, method of using the polypeptide complex, and fusion protein complex thereof
WO2006002532A1 (en) Methods and compositions using cd3 agonists
WO2026082147A1 (zh) 一种双靶点受体激动剂融合蛋白及其应用
CN105254763B (zh) 一种重组促胰岛素分泌素融合蛋白、制备方法及其应用
CN114891090B (zh) 一种酰化的长效glp-1衍生物
MX2012005912A (es) Conjugado de polipeptido.
US11400135B2 (en) Compositions and methods for treating obesity and hyperphagia
WO2022143516A1 (zh) 一种人glp-1多肽变体及其应用
WO2021083306A1 (zh) Glp-1/gcg双受体激动剂多肽
JP6033433B2 (ja) アポリポタンパク質aivを用いて高血糖障害を治療する方法
JP2008546816A (ja) エキセンディン4ポリペプチドフラグメントおよびその使用